RT Journal Article
SR Electronic
T1 Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.29.24303243
DO 10.1101/2024.02.29.24303243
A1 Barnes, Daniel R.
A1 Tyrer, Jonathan P.
A1 Dennis, Joe
A1 Leslie, Goska
A1 Bolla, Manjeet K.
A1 Lush, Michael
A1 Aeilts, Amber M.
A1 Aittomäki, Kristiina
A1 Andrieu, Nadine
A1 Andrulis, Irene L.
A1 Anton-Culver, Hoda
A1 Arason, Adalgeir
A1 Arun, Banu K.
A1 Balmaña, Judith
A1 Bandera, Elisa V.
A1 Barkardottir, Rosa B.
A1 Berger, Lieke P.V.
A1 Berrington de Gonzalez, Amy
A1 Berthet, Pascaline
A1 Białkowska, Katarzyna
A1 Bjørge, Line
A1 Blanco, Amie M.
A1 Blok, Marinus J.
A1 Bobolis, Kristie A.
A1 Bogdanova, Natalia V.
A1 Brenton, James D.
A1 Butz, Henriett
A1 Buys, Saundra S.
A1 Caligo, Maria A.
A1 Campbell, Ian
A1 Castillo, Carmen
A1 Claes, Kathleen B.M.
A1 GEMO Study Collaborators
A1 EMBRACE Collaborators
A1 Colonna, Sarah V.
A1 Cook, Linda S.
A1 Daly, Mary B.
A1 Dansonka-Mieszkowska, Agnieszka
A1 de la Hoya, Miguel
A1 deFazio, Anna
A1 DePersia, Allison
A1 Ding, Yuan Chun
A1 Domchek, Susan M.
A1 Dörk, Thilo
A1 Einbeigi, Zakaria
A1 Engel, Christoph
A1 Evans, D. Gareth
A1 Foretova, Lenka
A1 Fortner, Renée T.
A1 Fostira, Florentia
A1 Foti, Maria Cristina
A1 Friedman, Eitan
A1 Frone, Megan N.
A1 Ganz, Patricia A.
A1 Gentry-Maharaj, Aleksandra
A1 Glendon, Gord
A1 Godwin, Andrew K.
A1 González-Neira, Anna
A1 Greene, Mark H.
A1 Gronwald, Jacek
A1 Guerrieri-Gonzaga, Aliana
A1 Hamann, Ute
A1 Hansen, Thomas v.O.
A1 Harris, Holly R.
A1 Hauke, Jan
A1 Heitz, Florian
A1 Hogervorst, Frans B.L.
A1 Hooning, Maartje J.
A1 Hopper, John L.
A1 Huff, Chad D
A1 Huntsman, David G.
A1 Imyanitov, Evgeny N.
A1 kConFab Investigators
A1 Izatt, Louise
A1 Jakubowska, Anna
A1 James, Paul A.
A1 Janavicius, Ramunas
A1 John, Esther M.
A1 Kar, Siddhartha
A1 Karlan, Beth Y.
A1 Kennedy, Catherine J.
A1 Kiemeney, Lambertus A.L.M.
A1 Konstantopoulou, Irene
A1 Kupryjanczyk, Jolanta
A1 Laitman, Yael
A1 Lavie, Ofer
A1 Lawrenson, Kate
A1 Lester, Jenny
A1 Lesueur, Fabienne
A1 Lopez-Pleguezuelos, Carlos
A1 Mai, Phuong L.
A1 Manoukian, Siranoush
A1 May, Taymaa
A1 McNeish, Iain A.
A1 Menon, Usha
A1 Milne, Roger L.
A1 Modugno, Francesmary
A1 Mongiovi, Jennifer M.
A1 Montagna, Marco
A1 Moysich, Kirsten B.
A1 Neuhausen, Susan L.
A1 Nielsen, Finn C.
A1 Noguès, Catherine
A1 Oláh, Edit
A1 Olopade, Olufunmilayo I.
A1 Osorio, Ana
A1 Papi, Laura
A1 Pathak, Harsh
A1 Pearce, Celeste L.
A1 Pedersen, Inge S.
A1 Peixoto, Ana
A1 Pejovic, Tanja
A1 Peng, Pei-Chen
A1 Peshkin, Beth N.
A1 Peterlongo, Paolo
A1 Powell, C. Bethan
A1 Prokofyeva, Darya
A1 Pujana, Miquel Angel
A1 Radice, Paolo
A1 Rashid, Muhammad U.
A1 Rennert, Gad
A1 Richenberg, George
A1 Sandler, Dale P.
A1 Sasamoto, Naoko
A1 Setiawan, Veronica W.
A1 Sharma, Priyanka
A1 Sieh, Weiva
A1 Singer, Christian F.
A1 Snape, Katie
A1 Sokolenko, Anna P.
A1 Soucy, Penny
A1 Southey, Melissa C.
A1 Stoppa-Lyonnet, Dominique
A1 Sutphen, Rebecca
A1 Sutter, Christian
A1 Teixeira, Manuel R.
A1 Terry, Kathryn L.
A1 Thomsen, Liv Cecilie V.
A1 Tischkowitz, Marc
A1 Toland, Amanda E.
A1 Van Gorp, Toon
A1 Vega, Ana
A1 Velez Edwards, Digna R.
A1 Webb, Penelope M.
A1 Weitzel, Jeffrey N.
A1 Wentzensen, Nicolas
A1 Whittemore, Alice S.
A1 Winham, Stacey J.
A1 Wu, Anna H.
A1 Yadav, Siddhartha
A1 Yu, Yao
A1 Ziogas, Argyrios
A1 Berchuck, Andrew
A1 Couch, Fergus J.
A1 Goode, Ellen L.
A1 Goodman, Marc T.
A1 Monteiro, Alvaro N.
A1 Offit, Kenneth
A1 Ramus, Susan J.
A1 Risch, Harvey A.
A1 Schildkraut, Joellen M.
A1 Thomassen, Mads
A1 Simard, Jacques
A1 Easton, Douglas F.
A1 Jones, Michelle R.
A1 Chenevix-Trench, Georgia
A1 Gayther, Simon A.
A1 Antoniou, Antonis C.
A1 Pharoah, Paul D.P.
A1 the Ovarian Cancer Association Consortium and the Consortium of Investigators of Modifiers of BRCA1 and BRCA2
YR 2024
UL http://medrxiv.org/content/early/2024/03/04/2024.02.29.24303243.abstract
AB Background Nineteen genomic regions have been associated with high-grade serous ovarian cancer (HGSOC). We used data from the Ovarian Cancer Association Consortium (OCAC), Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA), UK Biobank (UKBB), and FinnGen to identify novel HGSOC susceptibility loci and develop polygenic scores (PGS).Methods We analyzed >22 million variants for 398,238 women. Associations were assessed separately by consortium and meta-analysed. OCAC and CIMBA data were used to develop PGS which were trained on FinnGen data and validated in UKBB and BioBank JapanResults Eight novel variants were associated with HGSOC risk. An interesting discovery biologically was finding that TP53 3’-UTR SNP rs78378222 was associated with HGSOC (per T allele relative risk (RR)=1.44, 95%CI:1.28-1.62, P=1.76×10-9). The optimal PGS included 64,518 variants and was associated with an odds ratio of 1.46 (95%CI:1.37-1.54) per standard deviation in the UKBB validation (AUROC curve=0.61, 95%CI:0.59-0.62).Conclusions This study represents the largest GWAS for HGSOC to date. The results highlight that improvements in imputation reference panels and increased sample sizes can identify HGSOC associated variants that previously went undetected, resulting in improved PGS. The use of updated PGS in cancer risk prediction algorithms will then improve personalized risk prediction for HGSOC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementA complete funding statement can be found in the Acknowledgements and Funding section.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UKBiobank data have been used under the access application with ID: 28126. All participating studies were approved by the relevant research ethics committee, and all participants provided written, informed consent. Full details are given in the Supplementary Text.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesSummary statistics produced in the present study are available upon reasonable request to the authors.